AirSculpt (AIRS) Q3 2026 Earnings Call Transcript

AirSculpt reported Q3 2026 revenue of $31.9 million, down 8.7% year over year, and adjusted EBITDA of about $0.4 million versus $3 million a year earlier; case volume fell 9.6% on a same-center basis. The company cut full-year revenue guidance to $144–$146 million from $151–$157 million and adjusted EBITDA guidance to $9–$10 million from $12–$14 million, citing lower Google search leads, higher acquisition costs and challenges at several centers. AirSculpt refinanced with a $44 million facility maturing in 2031, but its rate of SOFR plus 775 basis points is 300 basis points above the previous facility. GLP-1-related procedures were 250 cases, nearly 10% of Q3 volume; management cited a potential $100 million revenue opportunity across its existing centers.

Analysis

AIRS’ central risk is not simply weaker discretionary demand: its customer-acquisition funnel appears more exposed to a distribution change than to a temporary marketing shortfall. If AI summaries suppress clicks, shifting spend to local/brand channels may preserve leads but could take time and require higher cost; stable conversion after a lead arrives does not prove the economics of replacing lost traffic. The combination of lower case volume, higher acquisition cost and sharply reduced EBITDA makes Q4 execution especially consequential. Refinancing extends the maturity wall, but the 300bp higher spread increases the cost of a business whose earnings cushion has narrowed; verify the credit agreement’s covenants, amortization and current SOFR before quantifying coverage risk.

Near term, the open-house event and center-level fixes are observable tests, not yet evidence of a durable recovery. Over 1–3 months, watch lead volume, CAC, cases per center and EBITDA against the lowered outlook. Over 6–18 months, GLP-1-related procedures could broaden the addressable market, but the stated opportunity is not a forecast: commercialization, patient acquisition economics and procedure-level profitability remain unproven. Competitors with stronger local referral networks or less search-dependent acquisition could gain share; the effect on Alphabet is unlikely to be material absent broader evidence across advertisers. Contrarian angle: management may be right that demand persists and the issue is funnel capture, but the market could underweight how persistently AI search changes acquisition economics. Thesis fails if AIRS restores lead volume without further CAC escalation and stabilizes same-center cases and EBITDA; worsens if those metrics keep deteriorating or covenant headroom tightens.

Key Decisions for Investors

• Favor an underweight/avoid stance on AIRS over the next quarter; do not treat the extended 2031 maturity as resolution of operating or interest-cost risk. Reassess after Q4 results and the next guidance update.
• For a bearish expression, consider a small defined-risk AIRS put spread only after checking option liquidity and implied volatility; otherwise use a reduced/short cash position with disciplined risk limits. Avoid an unsupported price target.
• Track monthly/quarterly lead counts, CAC, same-center case volume, center-level recovery and adjusted EBITDA. If leads stabilize while CAC falls and cases recover, cover/revisit the bearish thesis; continued deterioration or guidance cuts strengthen it.
• Treat GLP-1 procedures and alloClae as watch items, not a standalone long catalyst, until AIRS discloses sustained volume growth and credible procedure-level economics. Verify utilization and contribution before underwriting the claimed opportunity.